Flanagan W. Michael bought RNA
December 17, 2025 · Form 4 insider transaction
Flanagan W. Michael bought 27,500 shares of Atrium Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Footnotes
Represents shares acquired upon the vesting of performance-based restricted stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on October 30, 2024. The PSUs were accelerated and settled on December 17, 2025 for tax planning purposes and such shares remain subject to recoupment by the Issuer if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason.